Augmenix Inc. said this week that it launched its SpaceOar hydrogel device in Israel. The Bedford, Mass.-based company’s absorbable prostate-rectum spacer is designed to reduce rectal injury during prostate radiotherapy. “We are excited to offer our patients this new, innovative technology to significantly reduce risks of prostate cancer radiotherapy,” Dr. Zvi Symon, from the Chaim […]
Augmenix
Augmenix touts long-term data for hydrogel spacer in prostate cancer patients
Augmenix Inc. said today that long-term outcomes data from the company’s phase III clinical trial evaluating its hydrogel spacer, SpaceOAR, were published in the International Journal of Radiation Oncology Biology and Physics. The spacer is designed to separate the rectum and prostate during prostate cancer radiotherapy, according to the Waltham, Mass.-based company. The newly published data were […]
